Akano Yumiko, Kuribayashi Kozo, Funaguchi Norihiko, Koda Yuichi, Fujimoto Eriko, Mikami Koji, Minami Toshiyuki, Takahashi Ryo, Yokoi Takashi, Kijima Takashi
Department of Internal Medicine, Division of Respiratory Medicine, Hyogo College of Medicine, Hyogo, Japan.
Department of Internal Medicine, Division of Respiratory Medicine, Hyogo College of Medicine, Hyogo, Japan
In Vivo. 2019 Mar-Apr;33(2):507-514. doi: 10.21873/invivo.11503.
BACKGROUND/AIM: Nivolumab is an immune checkpoint inhibitor for advanced non-small cell lung cancer (NSCLC). We investigated the safety and efficacy of nivolumab by analyzing the response factor, adverse effects (AE), and the post-treatment condition of pretreated advanced or recurrent NSCLC patients.
Nivolumab (3 mg/kg) was administered to 79 pre-treated NSCLC patients from December 2015 to January 2018. Nivolumab efficacy and AE were assessed using the Response Evaluation Criteria in Solid Tumors and the Common Terminology Criteria, respectively.
Progression-free survival (PFS) was significantly prolonged in cases where the therapeutic effect of the pretreatment was a partial response (p=0.0004). Five cases (6.3%) experienced grade 3-4 AEs. PFS was significantly prolonged in the skin rash group versus the non-skin rash group, and in patients where nivolumab treatment was discontinued.
Long-term survival was observed in patients with skin rash. Therapeutic effect of nivolumab immediately following its administration appears to be favorable for survival.
背景/目的：纳武单抗是一种用于晚期非小细胞肺癌（NSCLC）的免疫检查点抑制剂。我们通过分析预处理的晚期或复发性NSCLC患者的反应因素、不良反应（AE）和治疗后状况，研究了纳武单抗的安全性和疗效。
2015年12月至2018年1月，对79例预处理的NSCLC患者给予纳武单抗（3mg/kg）。分别采用实体瘤疗效评价标准和通用术语标准评估纳武单抗的疗效和AE。
预处理治疗效果为部分缓解的病例中，无进展生存期（PFS）显著延长（p=0.0004）。5例（6.3%）出现3-4级AE。皮疹组的PFS显著长于非皮疹组，且纳武单抗治疗中断的患者PFS也显著延长。
皮疹患者观察到长期生存。纳武单抗给药后立即出现的治疗效果似乎有利于生存。
